Why the study?
NAFLD is linked to metabolic syndrome and cardiovascular complications, but the bidirectional association between NAFLD and CAD mediated by endothelial dysfunction warrants examination to optimize management strategies.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Endothelial dysfunction may link NAFLD to CAD; hypothesis-generating and requires prospective validation before guiding practice.
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and is regarded as a liver manifestation of metabolic syndrome. It is linked to insulin resistance, obesity, and diabetes mellitus, all of which increase the risk of cardiovascular complications. Endothelial dysfunction (EnD) constitutes the main driver in the progression of atherosclerosis and coronary artery disease (CAD). Several pathophysiological alterations and molecular mechanisms are involved in the development of EnD in patients with NAFLD. Our aim is to examine the association of NAFLD and CAD with the parallel assessment of EnD, discussing the pathophysiological mechanisms and the genetic background that underpin this relationship. This review delves into the management of the condition, exploring potential clinical implications and available medical treatment options to facilitate the deployment of optimal treatment strategies for these patients.
No takes yet. Share an insight, caveat, or question.
Ktenopoulos et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: